Gsk Share Discussion Threads

[mani2013] 13/12/2017 08:59

Woodhawk,

I assume you are refering to 15981. It was a more of an addendum rather than an edit.

I am a full time day trader. I work from 07:00am to 07:00pm (currency markets after 16:30). I don't have the time to put up a full blown assessment of the movement on the forum like some of you do. It would take too long to explain the price behaviour and justify the thought processes.

Trading is all about probabilities. You can't always get it right. That's why you use stop losses.

There will more than likely be a pullback towards on the 60m chart towards the 1270 low. If the low holds it will a good sign that the selling pressure on the daily is subsiding and a potential turnaround. It will be a good buying opportunity for long term buyers.

If it breaks the low then the downtrend on the Daily continues.

It's that simple :)

As I write this, I missed a trade on the 5 min chart. I can see why professional traders don't participate on these forums.

My main objective of posting here and other forums is to help other market participants, particularly long term buy and hold players, make better decisions at a technical level and not lose money.

If you don't want my advice that's fair enough. It's your loss :)

[woodhawk] 13/12/2017 08:28

mani2013,

I see you've now edited your original post to cover your ass. Pathetic. Filtered.

[mj19] 13/12/2017 08:16

Still holding 5000 shares for long term. Good luck to all and let's hope for a better share price in 2018

[mani2013] 12/12/2017 12:28

Woodhawk, I always do.

Patience is a virtue in the trading game :)

[woodhawk] 12/12/2017 12:24

Enjoy your wait then, mani2013.

[gbh2] 12/12/2017 11:45

I jumped back in here @ 1280p, sold out day before last ex divi date but can't see that happening again now we appear to have a turn round.

I also have few IMM from 113p but just a speculative punt because I'm not overly keen on holding AIM companies.

[tradermichael] 12/12/2017 11:08

Q3 Dividend pays out 11 Jan
Q4 Dividend xd date is 22 Feb

[ny boy] 12/12/2017 10:28

Not really (IMM) has a very good story so far, all news flow is good, has been seriously undervalued, I started buying 52p, must be worth 250p as it stands, also rare for a small Company they own 100% of Lupuzor, if FDA approval follows, they have fast track already, the upsides are huge on a big pharma take out £20-100+ a share imho. I have absolutely no problems holding that one!!

Back to GSK I am holding a very large quantity and happy with quarterly divis, I am sure capital growth will follow.

GLA

[tradermichael] 12/12/2017 10:24

Anyway, IN @ 1312.835 ....... ;0)

[tradermichael] 12/12/2017 10:22

Correct - its not what she's doing, its what she said she might do!

[romeike] 12/12/2017 10:19

Emma W making the right moves. Just wish she'd stay clear of analysts.

[tradermichael] 12/12/2017 09:55

Its a L O N G climb back up, even longer if Emma blunders again ..... ;0)

[mani2013] 12/12/2017 08:22

BUY Signal on the 60 min (at last !!). 60m Chart downtrend broken.

DAILY is still in downtrend and could potentially create a swing point for the downtrend to continue in the next few days.

Situation is still precarious for LONG TERM investors. Enter on pullbacks and don't forget to use stops !

Please DYOR :)

[cwa1] 12/12/2017 07:59

Promising data for GSK2857916 at ASH meeting

[alphorn] 11/12/2017 13:26

Agree, would take great care. Have not followed IMM - they are doing pivotal PIII trials?

[romeike] 11/12/2017 13:24

IMM been hyped to death here and elsewhere - going to be one hell of a crash if clinical trials fall flat

[top tips] 11/12/2017 11:38

ImmuPharma (IMM) get Phase 3 results for their lupus drug Lupuzor in Jan 2018, and indications from the Phase 2b results and ongoing excellent safety and tolerability in Phase 3, are that it will be better than GSK's lupus drug Benlysta. Time to get into IMM.

[tradermichael] 11/12/2017 09:24

Data from this ongoing trial will be presented on 11th December in an oral presentation at the 59th annual meeting of the American Society of Hematology meeting in Atlanta.

“Oncology R&D at GSK is focused on developing medicines with transformational potential for patients and we are pleased that our investigational antibody-drug conjugate is the first BCMA targeting agent to receive Breakthrough Therapy and PRIME designation,” Axel Hoos, Senior Vice President Oncology R&D, at GlaxoSmithKline noted.

“GSK plans to rapidly advance clinical trials with this promising therapy, alone and in combination with other therapies, to further investigate how GSK2857916 could benefit patients with multiple myeloma. The monotherapy data that we have seen for GSK2857916 support its transformational potential and we look forward to working with regulators as we progress the development program,” Hoos added.

[tradermichael] 11/12/2017 09:18

Good article, thanks :

"Meanwhile, GSK is poised to publish .... a study on the effectiveness of its antibody treatment, code-named GSK 2857916, for multiple myeloma.

Analysts at Bank of America said they expected GSK’s study to show “very impressive early data” on the basis of a journal abstract the firm published ahead of the conference."

[philanderer] 10/12/2017 20:54

'AstraZeneca and GSK start fightback after big year for blood cancer treatments'

[polaris] 09/12/2017 12:33

Hi,

Anyone got the likely date for the response to Sandoz's ANDA for a generic Advair? It was submitted in June and, after the failures of Mylan and Hikma, I wonder just how long GSK will continue to enjoy exclusivity.

Advair brings in about 750M GBP per Q in sales, as sales have been falling since the 2013 peak, and GSKs own figures for 2017 expected in Xs of 1bn GBP, even in the case that a generic made it to market in the 2nd half. Most forward estimates had a generic to market by the end of 2017. That certainly will not happen, although an approval might well be given by the end of the year.

All the same, that is a whole boat load of cash that GSK continue to receive Q by Q while this resolves itself. I'd expect Sandoz and Hikma to make it to market sometime in the next 6-18 months (i think Mylan is least likely of the three to get FDA approval after the major) but Advair sales are not just going to go away, as pricing pressure will depend on how many generics and the timescales.

regards,

Paul

[ianood] 09/12/2017 11:10

gbh2 - yes, have appreciated a lot of your commentary over the years too!

[glavey] 09/12/2017 03:36

Very nice, but completely wrong forum.